AMANDA PRITCHETT: Open Payments
NPI 1184306011 · GREENWOOD, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,219 in 84 payments from 11 companies in 2025. Trend: 2023 $3,063 · 2024 $758 · 2025 $1,219
Food & beverage: $1,219
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 25 | $394 |
| Alkermes, Inc. | 13 | $307 |
| ABBVIE INC. | 29 | $215 |
| Teva Pharmaceuticals USA, Inc. | 5 | $98 |
| Otsuka America Pharmaceutical, Inc. | 4 | $75 |
| Indivior Inc. | 2 | $33 |
| Braeburn Inc. | 2 | $30 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Gilead Sciences, Inc. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
Products named: CAPLYTA, VRAYLAR, VIVITROL, ARISTADA, UZEDY, REXULTI, ABILIFY ASIMTUFII, SUBLOCADE.
Industry payments across IN — which companies pay providers there.
